Background: Portal vein thrombosis (PVT) is common in cirrhosis. PVT is associated with high morbidity and mortality. Individual reports suggest that PVT occurs more frequently in patients with cirrhosis and inherited thrombophilia. The relationship between cirrhosis, PVT development, and inherited thrombophilia was explored in this study. The aim of the study was to determine whether cirrhotic patients with nontumoral PVT have an increased rate of inherited thrombophilia.
| INTRODUCTION
Cirrhosis was initially thought to predispose patients to a hemorrhagic state due to a decrease in liver synthetic function and reduced production of coagulation factors. 1 However, studies over the past decade now characterize cirrhosis as a precarious state existing with a "rebalanced" hemostasis. 1 This places patients at risk for bleeding, thrombosis, or sometimes both simultaneously. 1 PVT is a frequent and serious complication of cirrhosis, with prevalence between 7.4% and 16%. 2 PVT is associated with increased risk of hepatic decompensation and inferior overall survival in comparison with patients without PVT, and it may lead to inferior posttransplant outcomes. [3] [4] [5] Many risk factors for PVT development are well established, including reduced portal vein blood flow; however, the impact of hereditary thrombophilia remains controversial. 6, 7 Factor V Leiden (FVL), prothrombin G20210A, and methyltetrahydrofolate reductase (MTHFR) C677T are well-established risk factors for deep vein thrombosis (DVT) and pulmonary embolism. FVL and prothrombin G20210A mutations affect roughly 5% of the general population.
Whether inherited thrombophilia increases the risk of PVT development remains unclear, as recent consensus guidelines from the 7th International Coagulation in Liver Diseases Conference 8 state that thrombophilia likely plays a role in PVT development but make no strong recommendation regarding testing for these conditions in either a screening capacity before PVT diagnosis or confirmatory once thrombosis has developed, largely due to conflicting data on this topic. [8] [9] [10] [11] No systemic review or meta-analysis has been conducted to clarify this uncertainty, and the role of hereditary thrombophilia in patients with cirrhosis remains unknown. Prior studies assessed FVL and prothrombin G20210A in the development of acute PVT without excluding subjects with malignancy. 12 The aim of this study was to determine whether there is an increased rate of inherited thrombophilia in patients with cirrhosis who develop nontumoral PVT. Initial inherited thrombophilias of interest included common mutations such as protein C/S deficiency and prothrombin G20210A, FVL, and MTHFR C677T mutation. We hypothesized that there is an overall increased prevalence of inherited thrombophilia in cirrhotic patients who develop PVT. 
| MATERIALS AND METHODS

| Literature search strategy
| Study selection
Two independent reviewers (SM and JW) screened the remaining list of studies for articles related to the research question. Studies were excluded if PVT was associated with malignancy including hepatocellular carcinoma (eg, tumoral thrombosis), developed after the procedure (eg, transjugular intrahepatic portosystemic shunt), if there were no primary data, or if no control/comparison group was included. Non-English studies were also excluded.
| Data extraction
Studies that met inclusion criteria underwent a full-text review by the 2 independent reviewers (SM and JW). Any disagreements about inclusion were resolved by an independent third clinical reviewer (JS). Data extraction from each study meeting inclusion criteria included patient characteristics (age/sex), study-level characteristics (author, publication year, study design, enrollment period, target population, total number of patients), and events of interest pertinent to the research question (prevalence of inherited thrombophilia in patients with cirrhosis who developed PVT vs. those who did not develop PVT). This study did not require institutional review board approval because no identifiable patient information was available or extracted. and Laird random-effects ORs to obtain aggregate estimates of effect size and 95% confidence intervals (CIs) and to account for both between-and within-study variability. Between-study variability was assessed using Cochran's Q statistic (with P < 0.05 considered significant).
| Statistical analysis
| Heterogeneity and bias assessment
Between-study heterogeneity was calculated using I 2 index, with significant between-study variability if I 2 was >75%. 13 Publication bias was also determined by creating post hoc funnel plots due to the publication bias inherent to the available scientific literature.
| RESULTS
| Included studies
The search strategy resulted in a total of 8915 publications and adhered to the Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) statement ( Figure 1 ). After ensuring that no duplicates were present, 2893 article titles and abstracts were screened. A total of 25 articles underwent full-text review. After qualitative review of each study, 9 met inclusion criteria and were included in the meta-analysis. Articles that were excluded either contained no primary data (5) , no thrombophilia data (5) , duplicate data (3), no control (2), or incorrect clinical end points (1) . The landmark study from Nery et al 14 could not be included, as patient level data with the number of subjects with PVT and each individual inherited thrombophilia was unable to be discerned. Study level characteristics are found in Table 1 . A summary of the search results is presented in Figure 1 , reflecting PRISMA standards. No additional studies were appropriate for inclusion based on our a priori determined criteria.
In total, the 9 studies that met inclusion criteria comprised 1929 patients with cirrhosis. Overall prevalence of PVT was 6.4%.
Subjects with PVT (n = 125) were compared to subjects without PVT (n = 1804). Mean individual study age ranged from 43 to 62 years and were predominantly male. The majority of the cohort had advanced cirrhosis, with Child-Turcotte-Pugh Class B or C disease. Chronic hepatitis C infection was the leading etiology of cirrhosis, followed by alcohol-related liver disease. Overall prevalence of thrombophilia was as follows: 17.3% MTHFR, 6.7% FVL, and 5.4% prothrombin G20102A. Table 2 provides details on patient-level characteristics.
| Inherited thrombophilia and PVT
| FVL mutation
Eight studies were used to determine the association of FVL mutation (either heterozygosity or homozygosity) with the odds of PVT in patients with cirrhosis. Overall prevalence of FVL was 6.7%.
Heterogeneity between the studies was not significant (I 2 = 26%).
Overall, there was an increased prevalence of FVL in patients with cirrhosis who developed PVT, with an OR of 1.98 (95% CI, 1.06-3.68; P = 0.03) ( Figure 2A ).
| Prothrombin G20210A mutation
Seven studies were used to determine the association of prothrombin G20210A with PVT in cirrhosis. Overall prevalence of prothrombin G20210A (either heterozygosity or homozygosity) was 5.4%.
Heterogeneity between the studies was not significant (I 2 = 58%).
Prothrombin G20210A also increased the odds of PVT in cirrhosis, with an OR of 2.43 (95% CI, 1.07-5.53; P = 0.03) ( Figure 2B ). No primary data (n = 5)
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| MTHFR C677T mutation
Three studies were used to determine the prevalence of MTHFR C677T mutations in patients with cirrhosis who developed PVT.
MTHFR C677T mutation was the most common thrombophilia, with a prevalence of 17.3% in the entire cohort. Heterogeneity between the studies was not significant (I 2 = 70%). The measure of effect suggested no association of MTHFR C677T
with PVT in cirrhosis (OR, 1.54; 95% CI, 0.66-3.55; P = 0.32) ( Figure 2C ).
| Other thrombophilias
One study included in this meta-analysis evaluated the plasminogen activator inhibitor-1 (PAI-1) 4G/5G mutation and found a statistically significant increased prevalence in patients with cirrhosis who developed PVT. 15 However, no pooled measure of effect could be calculated with this single study.
| Bias assessment
No heterogeneity bias was observed in this analysis. I 2 was <75% in all thrombophilia that had a pooled measurable effect ( Figure 2 ). No publication bias based on funnel plot analysis was observed as well ( Figure 3 ).
| DISCUSSION
In this study, patients with cirrhosis had a greater prevalence of inherited thrombophilia than the general population, with rates between 5% and 17%. Of the 3 thrombophilias that had adequate data for statistical analysis, FVL and prothrombin G20210A mutation were significantly higher in patients with cirrhosis who de- 20 and in 4% to 17% of those with VTE. 21, 22 Taken in concert with the high prevalence of inherited thrombophilia in VTE from previous studies, our findings support consideration of testing for FVL and prothrombin G20210A mutations in patients with cirrhosis and newly diagnosed PVT.
While the optimal treatment choice remains controversial (eg, anticoagulation), we would suggest consultation with a hematologist to discern both the optimal treatment regimen and duration of therapy. The role of transjugular or transsplenic intrahepatic portosystemic shunts in the treatment of PVT in patients with cirrhosis with thrombophilia will also need to be addressed with future studies; however, the argument can be made that even if endovascular intervention is pursued, patients with thrombophilia likely will need anticoagulation even if mechanical portal vein recanalization is obtained. Consideration of consultation with a hematologist would also be helpful and should be sought once a thrombophilia has been diagnosed in the patient with cirrhosis and PVT.
While our data do not answer the question regarding the utility of universal screening in all patients with cirrhosis at risk for PVT, prevalence rates of thrombophilia in PVT are similar to other general medical conditions where universal screening is recommended (eg, breast and colon cancer). 23, 24 Research suggests that FVL and prothrombin G20210A mutations increase only the first but not recurrent DVT. 25 Other studies have shown that thrombophilia screening does not reduce the risk of DVT recurrence. 26 
TA B L E 2 (Continued)
Although this meta-analysis excluded neoplasms and inflammatory conditions to avoid heterogeneity and selection bias, previous research studies have also found these conditions to be independent risk factors for patients with cirrhosis without inherited thrombophilias to develop PVT. 27 Whether patients with tumoral PVT have an increased rate of inherited thrombophilias remains unclear and is an interesting avenue for future study. In general, data on inherited thrombophilia and risk of PVT in malignancy are limited;
however, several small studies have documented both FVL and prothrombin G20210A mutation as independent risk factors for VTE in malignancy with a similar 2-to 4-fold increased risk. 28, 29 Antiphospholipid antibodies and acquired resistance to activated F I G U R E 2 Pooled measure of effects for patients with cirrhosis with/without PVT and with/without presence of: A, Factor V Leiden (FVL); B, prothrombin mutation (PTG20210A); C, methyltetrahydrofolate reductase mutation (MTHFR C677T) protein C may also predispose independently to thrombosis in patients with malignancy. 29 The findings from this study warrant a renewed focus to better understand the role of prophylactic anticoagulation in patients with cirrhosis who are at a greater risk for PVT development, including those with inherited thrombophilia. To date, there has been only 1 controlled trial published on the effective use of prophylactic anticoagulation for patients with cirrhosis. 30 In this study, no patients receiving enoxaparin developed PVT after 96 weeks, while 36% of subjects in the nonanticoagulated group developed PVT; interestingly, there was a survival benefit with no significant increase in hemorrhagic events or adverse effects in the anticoagulated group. 30 We propose that anticoagulants should be studied for their potential to prevent PVT in patients with cirrhosis and inherited thrombophilia. Other studies were excluded due to lack of a control group. Furthermore, several studies included in the meta-analysis were only abstracts of lower quality (Table 3) . Additionally, the lack of clarity surrounding what imaging modality was used to diagnose PVT in several studies is somewhat limiting. Although there was an increased prevalence of MTHFR C677T mutation in the patient population of interest, there was no pooled statistically significant increased risk in PVT, and the inclusion of only 3 studies limited statistical power ( Figure 2C) and led to greater heterogeneity. Additionally, data for PAI-1 4G/5G polymorphism was even more limited, with 1 study. However, it is important to note that neither MTHFR or PAI-1 4G/5G polymorphisms are established risk factors for the development of DVT. No concrete conclusions about either of these inherited thrombophilias can be made at this time, but future research may establish this.
In summary, patients with cirrhosis and concomitant inherited thrombophilia FVL and prothrombin G20102A are at higher risk for developing PVT than those without thrombophilia, with a 2-fold increased risk of PVT. Data for confident conclusions regarding MTHFR C677T and PAI-1 4G/5G mutation are lacking at this time. Although we were unable to include a recent longitudinal study that found no relationship between thrombophilia and PVT risk, 14 our conflicting conclusion provides greater insight into the need to study this topic further.
Future prospective studies investigating thrombophilia screening in patients with cirrhosis after PVT diagnosis seems warranted to better understand the role of genetics and clotting risk in patients with chronic liver disease, with the goal of impacting patient-centered outcomes.
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